Defendant
1 case as defendant.
MSN Pharmaceuticals Inc. ("MSNPI") is a Delaware-incorporated generic drugmaker with its principal U.S. site at 20 Duke Road, Piscataway, New Jersey. It was established in 2014, and its finished-dosage facility was built in 2018. MSNPI is a wholly owned subsidiary of MSN Laboratories Private Limited ("MSN Labs") of Hyderabad, India; MSN Labs is privately held, with founder Dr. Manne Satyanarayana Reddy (Dr. MSN Reddy) as chairman and managing director. In a July 2025 Rule 7.1 disclosure, the defendants stated no public entity owns 10% or more of MSN Labs. Size figures are estimates: MSN Labs' own materials cite 11,000+ employees and turnover exceeding USD 1 billion in FY2024–25, while third-party databases range from roughly 8,000 to 14,000 employees — treat these as unverified.
Operations. MSNPI is a finished-dosage manufacturer and contract development and manufacturing (CDMO) arm for the MSN group, operating a ~225,000 sq ft facility on 15 acres in Piscataway. Dosage forms include immediate-, delayed- and extended-release tablets and capsules, oral/topical solutions and suspensions, and DEA-controlled substances. The parent MSN Labs manufactures active pharmaceutical ingredients (APIs) and finished formulations — its site advertises hundreds of APIs and formulations across multiple therapeutic categories — and is vertically integrated from API through finished dose.
Litigation posture. This is an operating company, not an NPE. In our tracked data MSN Pharmaceuticals appears once, as a defendant, with zero plaintiff cases. The single tracked matter is Merck Sharp & Dohme Corp. v. MSN Laboratories et al. in the U.S. District Court for the District of Delaware — a Hatch-Waxman ANDA patent suit, the typical posture for a generic filer. Delaware, not the Eastern District of Texas, is the venue.
Context. MSNPI and MSN Labs appear together in numerous public ANDA suits filed by brand manufacturers (e.g., Merck, Vanda, Onyx, AbbVie/Allergan, Gilead) across Delaware and New Jersey, reflecting MSNPI's role as the group's U.S. regulatory agent and commercial arm. Merck's complaint in the tracked case is standard ANDA infringement pleading; no merits determination is implied here.
Settled by consent judgment; unless authorized by the settlement agreement, MSN is enjoined from infringing the '708 patent, and all claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice.